In utero Hepatitis B Immunization during Fetal Surgery for Spina Bifida by Moehrlen, Ueli et al.








In utero Hepatitis B Immunization during Fetal Surgery for Spina Bifida
Moehrlen, Ueli ; Elrod, Julia ; Ochsenbein-Kölble, Nicole ; Berger, Christoph ; Speck, Roberto F ;
Mazzone, Luca ; Krähenmann, Franziska ; Zimmermann, Roland ; Meuli, Martin
Abstract: BACKGROUND Fetal surgery for spina bifida aperta may lead to significantly better outcomes
than postnatal repair, particularly regarding shunt-dependent hydrocephalus, independent ambulation,
and voiding functions. The ”Management of Myelomeningocele Study” (MOMS) represents the current
benchmark, also in terms of eligibility criteria. CASE REPORT A positive maternal hepatitis B virus
(HBV) status is a MOMS exclusion criterion. Here, we report on the first successful active and passive in
utero HBV vaccination of a spina bifida fetus carried by a HBV-positive mother undergoing maternal-fetal
surgery. The now 2-year-old infant is healthy, HBV negative, and drew maximal benefit from prenatal
surgery. DISCUSSION AND CONCLUSION Taken together, this patient benefitted maximally from
fetal surgery for spina bifida, despite meeting an exclusion criterion. Thus, generally speaking, eligibility
criteria for fetal surgery can be challenged under certain circumstances for the benefit of the patient.
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• In utero surgery for myelomeningocele may lead to better outcomes than postnatal repair, particu-
larly regarding shunt-dependent hydrocephalus, ambulation, and voiding functions.
• In utero manipulation potentially increases the risk of vertical mother-to-child transmission of infec-
tious disease, such as hepatitis B.
• The current standard postnatal immunization for hepatitis B is also highly effective in extremely pre-
mature babies.
Novel Insights 
• A maternal treatment and fetal vaccination has been devised to minimize the risk of hepatitis B virus 
(HBV) mother-to-child transmission and thus allowing for in utero myelomeningocele repair despite 
a positive maternal HBV status.
• The plan includes intramuscular active and passive fetal immunization during open maternal-fetal 
surgery, after opening the uterus and before beginning the fetal part of the surgery. Immunization was 
uneventful and was well tolerated by mother and fetus.
• Generally speaking, after the quintessence of a study is published, former study criteria may be replaced 
by well-argued principles of personalized medicine, as this may benefit the fetus without additional 
risk for the mother.
DOI: 10.1159/000503447
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Abstract
Background: Fetal surgery for spina bifida aperta may lead 
to significantly better outcomes than postnatal repair, par-
ticularly regarding shunt-dependent hydrocephalus, inde-
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ment of Myelomeningocele Study” (MOMS) represents the 
current benchmark, also in terms of eligibility criteria. Case 
Report: A positive maternal hepatitis B virus (HBV) status is 
a MOMS exclusion criterion. Here, we report on the first suc-
cessful active and passive in utero HBV vaccination of a spina 
bifida fetus carried by a HBV-positive mother undergoing 
maternal-fetal surgery. The now 2-year-old infant is healthy, 
HBV negative, and drew maximal benefit from prenatal sur-
gery. Discussion and Conclusion: Taken together, this pa-
tient benefitted maximally from fetal surgery for spina bifi- 
da, despite meeting an exclusion criterion. Thus, generally 
speaking, eligibility criteria for fetal surgery can be chal-
lenged under certain circumstances for the benefit of the 
patient. © 2019 S. Karger AG, Basel
Case Report
A clinically healthy, 29-year-old, 4th gravida, 3rd para, was re-
ferred to the Zurich Center for fetal diagnosis and therapy in July 
2016 for evaluation regarding eventual fetal surgery for spina bi-
fida. At 22+0 weeks of gestation, fetal magnetic resonance imaging 
and ultrasound confirmed lumbo-sacral myeloschisis (upper level 
lumbar 4), Chiari II malformation with cerebellar herniation (lev-
el C3), moderate bilateral ventriculomegaly (14 mm), normal fetal 
leg movements on both sides (including ankles), no foot deformi-
ties, and regular bladder filling. The karyotype was normal (male).
The only relevant maternal problem was chronic, most likely 
inactive, hepatitis B virus (HBV) infection; in fact, she was HBs 
antigen positive, anti-HBs negative, anti-HBc positive, BeAg nega-
tive, and anti-HBe positive, indicating chronic hepatitis B. HBV-
DNA was detectable by polymerase chain reaction, but the abso-
lute blood level was non-quantifiable (< 10 U/mL), yielding a very 
low risk for vertical mother-to-child transmission (MTCT) [1].
Taken together, apart from maternal HBV infection, mother 
and fetus were good candidates for prenatal spina bifida repair.
Since the expectant parents firmly declined termination of 
pregnancy and definitely wanted to pursue fetal surgery, a multi-
disciplinary expert team, including adult and pediatric infectious 
disease specialists with special hepatitis expertise, devised a mater-
nal treatment and fetal vaccination plan (Fig. 1) for minimizing the 
risk of HBV MTCT.
After extensive, multidisciplinary, full disclosure, non-direc-
tive prenatal counselling, informed written consent was obtained 
from both parents. 
Prior to the operation, the mother was given a 3-week antiviral 
therapy with tenofovir disoproxil fumarate (TDF) 245 mg/day. 
Subsequently, open maternal-fetal surgery was performed at 25+4 
weeks of gestation, including intramuscular active and passive fetal 
immunization with HBsAg (Engerix®-B 10) and HBV IgG (200 IU 
Hepatitis-B-Immunglobulin Behring) after opening the uterus and 
before beginning the fetal part of the operation (Fig. 2). Surgery and 
the postoperative course were uneventful until 32 weeks of gesta-
tion, when the baby was born by caesarean section due to intrac-
table premature labor. The newborn received another dose of active 
and passive immunization against HBV within the first hour of life. 
Adaptation was normal, and the patient was discharged 9 weeks 
later. He demonstrated a complete regression of the formerly 
marked cerebellar herniation, a mild ventriculomegaly without the 
need for shunting, and corpus callosum dysplasia. Clinically, he 
showed normal voiding functions including a normal bladder ma-
nometry and normal motor function of both lower extremities. 
Primary immunization was completed with additional doses of 
active HBV vaccine at 4, 12, and 20 weeks after birth according to 
the WHO recommendations [2] (Fig.  2). HBV serology at 15 
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Fig. 1. Treatment concept. Tenofovir was administered to the mother as of the 23rd week of pregnancy until af-
ter fetal myelomeningocele repair. Myelomeningocele repair was performed at 25+4 weeks of gestation, including 
intrauterine active and passive immunization. The newborn was actively and passively immunized within the 
first hour of life. Primary active immunization was completed by application of a dose at weeks 4, 12, and 20. 
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tive) and yielded an anti-HBs titer > 100 IE/L (anti-HBs IgG 264 
IE/L), a surrogate for full protection against hepatitis B. 
At 26 months of age, the patient presented with suspected aque-
ductal stenosis, mild supratentorial hydrocephalus (no need for 
shunting), hypoplasia of the corpus callosum, and partial splenium 
agenesis. At the repair site, the commonly found posterior tethering 
and a small dermoid cyst were identified. Voiding functions and leg 
mobility remained normal, and independent ambulation was pos-
sible. Mental, linguistic, and fine motor development was near nor-
mal, whereas gross motor skill development was slightly delayed. 
Discussion
A positive maternal HBV status is an exclusion crite-
rion according to the current protocol (MOMS). In the 
present case, we decided to offer maternal-fetal surgery 
despite the presence of maternal HBV infection and here-
by report on our approach, expose our arguments, ac-
tions, and results.
Definitely, in case of fetal rather than postnatal sur-
gery, the risk of vertical hepatitis B transmission should 
not be greater than in case of postnatal care. 
Normally, MTCT of HBV occurs following perinatal 
fetal exposure with maternal body fluids. The standard 
post-birth management of neonates with a HBV-positive 
mother would consist of active and passive immunization 
within the first hours of life [3, 4], which is very effective 
for preventing vertical HBV transmission [5–8], resulting 
in only 5% of all infants becoming chronic HBV carriers, 
equivalent to a reduction of MTCT of almost 90% [9–11].
The current standard postnatal immunization is also 
highly effective in premature babies: Song et al. [6] did not 
find any association between premature birth, low birth 
weight, and MTCT of HBV, and according to Omeñaca 
et al. [7], extremely preterm babies had a response to HBV 
vaccination at 2, 4, and 6 months similarly to full-term 
infants.
Based on the above considerations, a management 
plan was devised. By administering active and passive fe-
tal immunization to the patient after opening the uterus 
and before beginning the fetal part of the operation, and 
then also immediately after birth, we aimed at providing 
the best possible protection from peri- and postoperative 
as well as from birth-related transmission. By applying 
this regimen, the risk of the patient to get infected with 
HBV appeared very low.
In addition, low maternal HBV replication as in the 
present case is a favorable prognostic factor [12]. None-
theless, TDF is very effective in lowering the HBV titer 
[13, 14]; thus, the mother was prescribed TDF for 3 weeks.
Of note, our fetal surgery scenario exactly followed the 
above given plan, and we did not encounter any side ef-
fects from immunization or antiviral treatment. Notably, 
we have a large experience using TDF in HIV-infected 
pregnant mothers [15], and our data support the safety of 
TDF-FTC backbones, initiated in pregnancy with respect 
to gestational length and birthweight. On the other side, 
TDF and the administered immunization protected the 
patient from potential infection with HBV, now serolog-
ically excluded at the age of 2 years.
Importantly, there is compelling experimental [16] 
and clinical [17, 18] evidence that fetal surgery saves neu-
rological function. Without fetal surgery, this patient 
would have had an 82% probability of needing shunting 
for hydrocephalus [17], a high probability of having se-
vere irreversible neuropathic bladder and rectum [19], 
and of being wheelchair dependent for a lifetime.
This case exemplifies that the rigorous criteria for a 
randomized clinical trial must not necessarily be kept in 
place after the quintessence of the study is published. 
Rather, patients may receive a more appropriate treat-
ment and enjoy better outcomes when decision-making 
follows the principles of personalized medicine.
Fig. 2. In utero immunization. Intrauterine active and passive im-
munization was performed via intragluteal injection (white arrow) 
after opening the uterus, yet before commencing any surgical pro-
cedures on the fetus so as to impede contact of the fetal circulation 
with the HB virus before vaccination. Black arrows are hysteroto-
my edges, the asterisk denotes the uterus, and t is the rubber tube 
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